Watch The Webinar On Demand


Extracorporeal membrane oxygenation (ECMO) is an effective, lifesaving therapy that is constantly growing in use and provides a therapy that may replace the conventional options.1

Although reports on the use of ECMO from previous epidemics exist, dedicated guidelines were authored during the COVID-19 pandemic to help triage patients in the face of reduced resources.2 If you are involved in your institution’s ECMO program, you will not want to miss the information this webinar offers on ECMO and the COVID-19 pandemic.

Join Senior Clinical Support Specialist Lisa Soltis as she reviews:

  • Initial World Health Organization (WHO) and ELSO
  • (Extracorporeal Life Support Organization) guidelines in response to the COVID-19 pandemic
  • Expert consensus report on patient outcomes during COVID-19 published by the American Thoracic Society (ATS)
  • Recommended changes in current practice to standard ECMO therapy for venovenous (VV) support
  • Ongoing data from the ELSO Registry 
  • Discussion of changes from ATS and ELSO for improved patient outcomes

About the Presenter:

Melinda Keto, Senior Healthcare Consultant, Healthcare Design Specialists LLC

FMCNA Senior Clinical Support Specialist

Lisa Soltis is a critical care nurse with over 26 years of experience. In recent years, she has focused on mechanical circulatory support for critically ill patients, working as an ECMO Specialist, an ECMO Coordinator, and as a Director of ECMO Professional Development and Education. Currently, Lisa is a Senior Clinical Support Specialist with Fresenius Medical Care, Heart and Lung Therapies. She earned her BA from Western Michigan University, her BSN from the University of North Carolina–Charlotte, and her master’s degree from Duke University School of Nursing as an Adult Critical Care Clinical Nurse Specialist.


Watch Webinar now

Complete this form to watch the on-demand webinar.


1. Makhoul M, Bitton-Worms K, Adler Z, Saeed A, Cohen O, Bolotin Gv(2019). Extracorporeal Membrane Oxygenation
(ECMO)-A Lifesaving Technology. Review and Single-center Experience. Rambam Maimonides medical journal, 10(2), e0013.

2. Bertini P, Guarracino F, Falcone M, et al. ECMO in COVID-19 Patients: A Systematic Review and Meta-analysis.
J Cardiothorac Vasc Anesth. 2022;36(8 Pt A):2700-2706. doi:10.1053/j.jvca.2021.11.006


The Novalung® System is indicated for long-term (>6 hours) respiratory/cardiopulmonary support that provides assisted extracorporeal circulation and physiologic gas exchange (oxygenation and CO2 removal) of the patient’s blood in adults with acute respiratory failure or acute cardiopulmonary failure, where other available treatment options have failed, and continued clinical deterioration is expected or the risk of death is imminent. These may include: • Failure to wean from cardiopulmonary bypass following cardiac surgery in adult patients • ECMO-assisted cardiopulmonary resuscitation in adults 

CAUTION: Federal (US) law restricts these devices to sale by or on the order of a physician. 

NOTE: Read the Instructions for Use for safe and proper use of these devices. The Indications for Use for this device can be found at

© 2022 Fresenius Medical Care. All Rights Reserved. Fresenius Medical Care, the triangle logo, and Novalung are trademarks of Fresenius Medical Care Holdings, Inc. or its affiliated companies. All other trademarks are the property of their respective owners. P/N 105248-01 Rev A 10/2022